跳至主要内容
临床试验/NCT04247230
NCT04247230已完成1 期

An Open Label, Placebo and Positive Controlled, Randomised, Cross-over Study in Healthy Male Volunteers to Determine the Effect on Penile Skin Sensation of a Newly Formulated Tetracaine Product PET500

Futura Medical Developments Ltd.0 个研究点目标入组 20 人开始时间: 2008年9月3日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
20
主要终点
Onset of action of different doses of a newly formulated tetracaine spray PET500 when applied to the glans penis assessed using Von Frey fibres (monofilaments) to measure touch sensitivity

研究概览

简要总结

An open label, placebo and positive controlled, randomised, cross-over study in healthy male volunteers to determine the effect on penile skin sensation of a newly formulated tetracaine product PET500

详细描述

This was an open label, placebo and positive controlled, randomised, dose-ranging, cross-over pilot study.

On each dosing day the subjects each received one dose of tetracaine (0.26 or 0.65 or 1.3mg), or placebo, or Stud100® (which served as a positive control) on the glans penis The doses of PET500 were applied in liquid spray form (260μl) at approximately the same time of the day as the previous application to locations on the glans penis in a randomised fashion.

Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.

The first two volunteers included in the trial piloted the sensitivity assessments prior to the inclusion of all other subjects. Changes could be made to the assessment times on the basis of the pilot data to ensure subsequent timings were relevant. However any such changes were not to expose volunteers to more assessments than were specified in the study protocol.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Sequential
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • A subject will be eligible for inclusion in this study only if all of the following criteria apply:
  • Male healthy subject aged 18 to 65 years, inclusive.
  • The subject is capable of understanding and complying with protocol requirements.
  • The subject is in good health as determined by medical history and physical examination at screening.
  • The subject signs a written, informed consent form prior to the initiation of any study procedures

排除标准

  • A subject will not be eligible for inclusion in this study if any of the following criteria apply:
  • 1 History or hypersensitivity to tetracaine or ethanol.
  • History or signs of a sexually transmitted disease.
  • Any current penile abnormalities.
  • Known current drug abuser or alcoholic as determined by medical history.
  • Participation in a clinical trial within the last month prior to dosing on Day
  • The use of concomitant systemic or topical medications or foods that may affect the study outcome and / or impair drug metabolising capacity.
  • A positive HIV 1 & 2 antibodies, Hepatitis B surface antigen, and/or Hepatitis C antibody result.
  • Unfit to participate in the study in the opinion of the Principal Investigator.

研究组 & 干预措施

PET500 (0.1%)

Experimental

Each actuation of the pump spray dispenses 130µl PET500. Two pumps will dispense 260µl as follows:

PET500 (0.1%) corresponding to a tetracaine total dose of 0.26mg

干预措施: Tetracaine (Drug)

PET500 (0.25%)

Experimental

Each actuation of the pump spray dispenses 130µl PET500. Two pumps will dispense 260µl as follows:

PET500 (0.25%) corresponding to a tetracaine total dose of 0.65mg

干预措施: Tetracaine (Drug)

PET500 (0.5%)

Experimental

Each actuation of the pump spray dispenses 130µl PET500. Two pumps will dispense 260µl as follows:

PET500 (0.5%) corresponding to a tetracaine total dose of 1.3mg

干预措施: Tetracaine (Drug)

PET500 placebo comparator

Experimental

Each actuation of the pump spray dispenses 130µl PET500 [vehicle only]. Two pumps will dispense 260µl

干预措施: Matching placebo (PET500) (Other)

STUD100 (9.6%)

Active Comparator

Each actuation of the pump spray dispenses 130µl, corresponding to a dose of 7.7mg lidocaine. Three pumps will dispense 390µl of a 9.6% solution, delivering a total dose of 23mg lidocaine. UK License Number PL/2294/5000R

干预措施: STUD100 (Drug)

结局指标

主要结局

Onset of action of different doses of a newly formulated tetracaine spray PET500 when applied to the glans penis assessed using Von Frey fibres (monofilaments) to measure touch sensitivity

时间窗: 2 Months

To determine the onset of action of different doses of a newly formulated tetracaine spray PET500 when applied to the glans penis (compared to placebo and positive prilocaine/lidocaine control).

Duration of action of different doses of a newly formulated tetracaine spray PET500 when applied to the glans penis using Von Frey fibres (monofilaments) to measure touch sensitivity

时间窗: 2 Months

To determine the duration of action of different doses of a newly formulated tetracaine spray PET500 when applied to the glans penis (compared to placebo and positive prilocaine/lidocaine control).

次要结局

  • Incidence of adverse events for PET500(2 months)
  • Intensity and relationship of adverse events to PET500(2 months)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验